论文部分内容阅读
人的类淋巴母细胞干抚素(HLBI)是从培养B-urkitt 淋巴瘤Namalva 株用Sendai 病毒作诱导剂而产生的干扰素(INF)。它含α—INF 为85%～90%,B—INF 为10%～15%. 本文介绍用HLBI 治疗各种恶性肿瘤25例疗效观察及其副作用。病例选择原则是①经组织学及细胞学确诊为恶性肿瘤者,②有可能测定病变者,③以前经过治疗的必须观察4周以上不影响判定者,④PS(Karnofsky)为40%以上者,⑤骨髓、肝、心、肾功能无严重损害
Human lymphoblastoid stem cell factor (HLBI) is an interferon (INF) produced by the Sendai virus as an inducing agent in the culture of B-urkitt lymphoma Namalva strain. It contains α-INF of 85% to 90%, B-INF of 10% to 15% .This article describes the treatment of various malignancies with HLBI 25 cases of efficacy and side effects. Case selection principle ① histologically and cytologically diagnosed as malignant tumors, ② may determine the lesion, ③ previously treated must be observed for more than 4 weeks does not affect the judge, ④ PS (Karnofsky) for more than 40%, ⑤ Bone marrow, liver, heart and kidney function without serious damage